Cipla, Kemwell Biopharma announce JV for respiratory biosimilars

Mumbai-based pharma firm Cipla and Bengaluru-based contract development and manufacturing organisation (CDMO) Kemwell Biopharma have announced the execution of a joint venture (JV) agreement to develop, manufacture and commercialise biosimilars for global markets. For this purpose, a joint venture company shall be incorporated with an aim to enter the respiratory biosimilars space. Under the terms of the agreement, the joint venture will leverage Cipla and Kemwell’s complementary strengths for end-to-end product development, clinical development, regulatory filings, manufacturing and commercialisation of biopharmaceutical products. Cipla’s respiratory prowess combined with Kemwell’s expertise in biologics will accelerate bringing these essential products to market.